177 related articles for article (PubMed ID: 24825754)
1. The economic considerations and implications of the stratification of future oncology therapeutics.
Gazouli M; Souliotis K
Mol Diagn Ther; 2014 Aug; 18(4):403-8. PubMed ID: 24825754
[TBL] [Abstract][Full Text] [Related]
2. Economics of cancer biomarkers.
Schneider JE; Sidhu MK; Doucet C; Kiss N; Ohsfeldt RL; Chalfin D
Per Med; 2012 Nov; 9(8):829-837. PubMed ID: 29776231
[TBL] [Abstract][Full Text] [Related]
3. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.
Stahel R; Bogaerts J; Ciardiello F; de Ruysscher D; Dubsky P; Ducreux M; Finn S; Laurent-Puig P; Peters S; Piccart M; Smit E; Sotiriou C; Tejpar S; Van Cutsem E; Tabernero J
Cancer Treat Rev; 2015 Feb; 41(2):129-35. PubMed ID: 25533737
[TBL] [Abstract][Full Text] [Related]
4. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
5. [Today's cancer medicine: less could often be more].
Fey MF
Ther Umsch; 2014 Dec; 71(12):765-70. PubMed ID: 25447092
[TBL] [Abstract][Full Text] [Related]
6. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
7. Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise?
Morgan G; Aftimos P; Awada A
Curr Opin Oncol; 2016 Sep; 28(5):441-6. PubMed ID: 27428363
[TBL] [Abstract][Full Text] [Related]
8. Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs.
Nerich V; Borg C; Villanueva C; Thiery-Vuillemin A; Helias P; Rohrlich PS; Demarchi M; Pivot X; Limat S
J Oncol Pharm Pract; 2013 Mar; 19(1):8-17. PubMed ID: 22623276
[TBL] [Abstract][Full Text] [Related]
9. Oncology biomarkers--second annual GTCbio conference. Biomarkers for disease detection and therapeutics monitoring. 19-20 January 2009, Miami, FL, USA.
Scholler N
IDrugs; 2009 Apr; 12(4):207-10. PubMed ID: 19350459
[No Abstract] [Full Text] [Related]
10. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
11. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
12. Early detection and therapeutics.
Januszewicz W; Fitzgerald RC
Mol Oncol; 2019 Mar; 13(3):599-613. PubMed ID: 30677217
[TBL] [Abstract][Full Text] [Related]
13. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
14. Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.
Albaba H; Lim C; Leighl NB
Pharmacoeconomics; 2017 Dec; 35(12):1195-1209. PubMed ID: 28861770
[TBL] [Abstract][Full Text] [Related]
15. Cancer biomarkers: current issues and future directions.
Jain KK
Curr Opin Mol Ther; 2007 Dec; 9(6):563-71. PubMed ID: 18041667
[TBL] [Abstract][Full Text] [Related]
16. [Priority setting in scaled-up cancer screening in China: an systematic review of economic evaluation evidences].
Shi JF; Mao AY; Bai YN; Liu GX; Liu CC; Wang H; Cao MM; Feng H; Wang L; Bai FZ; Huang HY; Bai HJ; Zhu J; Yan XX; Zhang J; Ren JS; Li N; Dai M; Chen WQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Mar; 54(3):306-313. PubMed ID: 32187937
[No Abstract] [Full Text] [Related]
17. The impact of pricing strategy on the costs of oral anti-cancer drugs.
Truong J; Chan KKW; Mai H; Chambers A; Sabharwal M; Trudeau ME; Cheung MC
Cancer Med; 2019 Jul; 8(8):3770-3781. PubMed ID: 31132223
[TBL] [Abstract][Full Text] [Related]
18. Identification of target small molecule tyrosine kinase inhibitors that need monitoring and clinical application of protocol for early detection of cancer therapeutics-related cardiac dysfunction using signal detection: An investigation of real world data.
Mizuno T; Sakai T; Tanabe K; Kozaki K; Umemura T; Higashikawa M; Kimura T; Yamada T; Goto N; Ohtsu F
J Oncol Pharm Pract; 2021 Jun; 27(4):804-814. PubMed ID: 32539664
[TBL] [Abstract][Full Text] [Related]
19. Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development.
Beckman RA; Chen C
Adv Exp Med Biol; 2015; 867():81-90. PubMed ID: 26530361
[TBL] [Abstract][Full Text] [Related]
20. Update on urine as a biomarker in cancer: a necessary review of an old story.
Zhang W; Zhang XJ; Chao SY; Chen SJ; Zhang ZJ; Zhao J; Lv YN; Yao JJ; Bai YY
Expert Rev Mol Diagn; 2020 May; 20(5):477-488. PubMed ID: 32212972
[No Abstract] [Full Text] [Related]
[Next] [New Search]
